<DOC>
	<DOCNO>NCT00381888</DOCNO>
	<brief_summary>RATIONALE : Fondaparinux may help prevent blood clot form patient undergo surgery gynecologic cancer . PURPOSE : This phase II trial study well fondaparinux work prevent blood clot patient undergo surgery gynecologic cancer .</brief_summary>
	<brief_title>Fondaparinux Preventing Blood Clots Patients Undergoing Surgery Gynecologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate efficacy prolong ( 4 week ) fondaparinux sodium administration venous thromboembolism prophylaxis patient undergo gynecologic oncology surgery . Secondary - Evaluate safety regimen patient ( 4 week ) . - Determine feasibility regimen patient ( 4 week ) . OUTLINE : This open-label study . Beginning surgery , patient receive fondaparinux sodium subcutaneously daily day 1-28 absence disease progression unacceptable toxicity . Patients undergo duplex ultrasonography low extremity day 28-35 .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Inclusion Criteria Scheduled undergo major , open abdominalpelvic surgery know presumed gynecologic malignancy Age 18 year old time sign consent Gynecologic Oncology Group ( GOG ) performance status ≤ 2 Life expectancy &gt; 3 month Patient 's weight must ≥ 50 kg Adequate organ function within 28 day study entry define : Hemoglobin ≥ 9.0 g/dL Platelet ≥ 100,000 x 109/L Blood urea nitrogen ( BUN ) ≤ 30 mg/dL Serum creatinine ≤ 1.5 mg/dL Not pregnant determine negative urine serum pregnancy test within 14 day study enrollment Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Exclusion Criteria Current treatment anticoagulant Thromboembolism within previous 6 month Bleeding/blood disorder ( e.g. , thrombocytopenia ) , gastrointestinal bleeding ( e.g. , active ulcer ) , history stroke within past 3 year , severe currently uncontrolled high blood pressure Bacterial endocarditis Known hypersensitivity fondaparinux sodium</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>thromboembolism</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>endometrial cancer</keyword>
	<keyword>ovarian epithelial cancer</keyword>
	<keyword>ovarian germ cell tumor</keyword>
	<keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>uterine sarcoma</keyword>
	<keyword>vaginal cancer</keyword>
	<keyword>vulvar cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
</DOC>